<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=iso-8859-1"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0cm;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
span.EmailStyle19
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:windowtext;}
span.EmailStyle21
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>See note below wrt a survey. <o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Thx.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Anne Breakey Hart [mailto:anne.breakeyhart@prostatecancer.ca] <br><b>Sent:</b> April 23, 2018 1:43 PM<br><b>To:</b> Anne Breakey Hart<br><b>Subject:</b> Interesting Survey to consider doing!<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span style='color:#1F497D'>Hello Everyone,<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>I want to let you know about an interesting survey that the Canadian Cancer Survivor Network is distributing this week. Some of you may have already received this however if not I want to make sure that you do receive it.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Please note that the survey is related to a new medication called apalutamide to be used for treatment with non-metastatic castration-resistant prostate cancer. Please see the details and the survey link below.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;background:white'><o:p> </o:p></span></p><p class=MsoNormal><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;background:white'>The purpose of the survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about living with and managing prostate cancer from patients and caregivers in order to complete a patient evidence submission for a new medication for <strong><span style='font-family:"Arial","sans-serif";border:none windowtext 1.0pt;padding:0cm'>non-metastatic castration-resistant prostate cancer</span></strong> called <strong><span style='font-family:"Arial","sans-serif";border:none windowtext 1.0pt;padding:0cm'>apalutamide </span></strong>(brand name Erleada<sup>TM</sup>)<strong><span style='font-family:"Arial","sans-serif";border:none windowtext 1.0pt;padding:0cm'>. </span></strong><b><span style='border:none windowtext 1.0pt;padding:0cm'><br><br><strong><span style='font-family:"Arial","sans-serif"'>At this time we are looking for patients and their caregivers who feel they would benefit from or could have benefitted from this treatment to participate. This primarily includes men with non-metastatic castration-resistant prostate cancer, men with metastatic castration-resistant prostate cancer and men who are currently on hormone therapy/ADT as well as their caregivers. If you are a patient outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well.</span></strong></span></b></span><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black'><br><br><span style='background:white'>The pan-Canadian Oncology Drug Review invites patient groups like CCSN to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.<o:p></o:p></span></span></p><p class=MsoNormal><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;background:white'><o:p> </o:p></span></p><p class=MsoNormal><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;background:white'>Please click on the link here: </span><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.surveymonkey.com_r_RBGBFYC&d=DwMFaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=9heIRYwvZvK9YiTp6EmYB7x3ah4npZ0w1FDGBX0pzOw&m=g3U241KqoUUxwZ3cbLIPMYCtUoii3PRxGPUBMp7bNOM&s=JSyBM8DDa4esFil2ws5ySo7_58CCY27y5wxlSerbe0Y&e=">https://www.surveymonkey.com/r/RBGBFYC</a><span style='font-size:12.0pt;font-family:"Times New Roman","serif"'><o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black'><br><b><span style='background:white'>The survey will be available starting now and remain open until April 30, 2018.</span></b><br><br><span style='background:white'>Thank you for your participation.<o:p></o:p></span></span></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span style='color:#1F497D'>Anne<o:p></o:p></span></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0070C0'>Anne Breakey Hart, CVA<br></span></b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0070C0'>Manager, PCCN and Volunteer Engagement | Prostate Cancer Canada<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0070C0'>Gestionnaire,</span><span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'> Mobilisation des bénévoles </span><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0070C0'>| Cancer de la Prostate Canada</span><span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'><o:p></o:p></span></p><p class=MsoNormal><b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0070C0'>T </span></b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0070C0'>416-441-2131 ext./poste 229 | <b>E</b></span><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'> </span><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#1F497D'><a href="mailto:anne.breakeyhart@prostatecancer.ca">anne.breakeyhart@prostatecancer.ca</a></span><span style='color:#1F497D'><o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><a href="www.prostatecancer.ca">www.prostatecancer.ca</a><o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><img border=0 width=250 height=93 id="Picture_x0020_4" src="cid:image001.png@01D3DB07.8FF94B50" alt="cid:image001.png@01D06C88.6A54F890"><o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><a href="http://www.facebook.com/prostatecancercanada"><span style='text-decoration:none'><img border=0 width=24 height=24 id="Picture_x0020_3" src="cid:image002.png@01D3DB07.8FF94B50" alt=facebook></span></a><span style='color:#1F497D'> </span><a href="http://www.twitter.com/prostatecancerc"><span style='text-decoration:none'><img border=0 width=24 height=24 id="Picture_x0020_2" src="cid:image003.png@01D3DB07.8FF94B50" alt=twitter></span></a><span style='color:#1F497D'> </span><a href="youtube.com/prostatecancercanada"><span style='text-decoration:none'><img border=0 width=24 height=24 id="Picture_x0020_1" src="cid:image004.png@01D3DB07.8FF94B50" alt=Youtube></span></a><o:p></o:p></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><b><span style='color:#0070C0'>Looking for information about prostate cancer? </span></b><span style='color:#0070C0'>Just found out you have prostate cancer? Help is here. Call 1 -855-PCC-INFO (1-855-722-4636) or email<b> </b><a href="mailto:support@prostatecancer.ca">support@prostatecancer.ca</a><o:p></o:p></span></p><p class=MsoNormal><b><span style='color:#0070C0'><o:p> </o:p></span></b></p><p class=MsoNormal><b><span lang=FR-CA style='color:#0070C0'>Cherchez-vous de l’information sur le cancer de la prostate? </span></b><span lang=FR-CA style='color:#0070C0'>Venez-vous de recevoir un diagnostic de cancer de la prostate? Nous sommes là pour vous aider. Composez le 1-855-PCC-INFO (1-855-722-4636) ou écrivez-nous par courriel à </span><span style='color:#0070C0'><a href="mailto:soutien@prostatecancer.ca"><span lang=FR-CA>soutien@prostatecancer.ca</span></a></span><span lang=FR-CA style='color:#0070C0'><o:p></o:p></span></p><p class=MsoNormal><span lang=FR-CA><o:p> </o:p></span></p><p class=MsoNormal><span lang=FR-CA><o:p> </o:p></span></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=FR-CA style='color:#0070C0'><o:p> </o:p></span></p><p class=MsoNormal><span lang=FR-CA><o:p> </o:p></span></p><p class=MsoNormal><span lang=FR-CA><o:p> </o:p></span></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span lang=FR-CA><o:p> </o:p></span></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><o:p> </o:p></p></div></body></html>